Psychedelics


PharmAla Biotech Becomes First Publicly Traded Company to Produce GMP MDMA

August 17th, 2022 - Ryan Allway

PharmAla’s GMP LaNeo MDMA has completed all release testing, is ready for export VANCOUVER, August 17, 2022 (Canada Newswire) – PharmAla Biotech (CSE:MDMA) (the ‘Company’) has achieved a historic milestone: it is currently the only publicly-traded company to have produced GMP MDMA at scale. The company believes that it is currently the only source for […]

Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial

August 17th, 2022 - Ryan Allway

TORONTO–(BUSINESS WIRE)– Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, and its partner Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, today announced that the U.S. Drug Enforcement Agency (“DEA”) has granted a Schedule I license to […]

Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health

August 16th, 2022 - Ryan Allway

CEO says licensing amendment positions Optimi to be a “global leader in the safe supply of EU-GMP Psilocybin, MDMA, and other psychedelics” VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms for transformational […]

Irwin Naturals Emergence Adds New England Clinic to Its National Footprint

August 15th, 2022 - Ryan Allway

Vermont ketamine treatment facility added to fast-growing chain of psychedelic mental-health clinics   LOS ANGELES, Aug. 15, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) completed the acquisition of its first Vermont clinic, continuing what has been the rapid expansion of this nationally known brand name into the emerging […]

Optimi Health To Launch Therapeutic Psilocybin Product In Partnership With Patient Advocate Thomas Hartle

August 8th, 2022 - Ryan Allway

VANCOUVER, British Columbia, Aug. 08, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms, as well as synthetic formulations for transformational human experiences, is pleased to announce that it has entered […]

Irwin Naturals Completes Georgia Acquisition, Adds Two Ketamine Clinics to National Chain

August 8th, 2022 - Ryan Allway

The national chain of psychedelic mental-healthcare clinics growing rapidly LOS ANGELES, Aug. 08, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) completed the acquisition of two ketamine clinics in Georgia through an asset purchase of Invictus Clinics, LLC, which will be brought into the fast-growing national chain of psychedelic […]

PharmAla Biotech named Exclusive MDMA Supplier to InterVivo Solutions

August 5th, 2022 - Ryan Allway

PharmAla to supply InterVivo and its Clients for the purposes of scientific research   VANCOUVER, BC and TORONTO, Aug. 5, 2022 /CNW/ – PharmAla Biotech (CSE: MDMA) is pleased to announce that it has signed on to act as exclusive supplier of both GMP LaNeo™ MDMA and Engineering MDMA to InterVivo Solutions (Toronto), its client […]

Braxia Scientific Enters U.S. Telemedicine Industry; Acquires KetaMD, a Mental Health Platform Providing Beneficial Ketamine Treatments in Florida with plans to expand across the U.S.

August 3rd, 2022 - Ryan Allway

TORONTO, Aug. 3, 2022 /CNW/ – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FSE: 4960), a leader in the treatment and research of mental health conditions, is pleased to announce it has acquired 100% of the issued and outstanding stock of KetaMD, Inc. (“KetaMD”) (the “Transaction”). KetaMD is a U.S. based, privately-held, […]

PharmaDrug Announces Non-Brokered Offering of $650,000 of Convertible Secured Debentures and Issuances of Common Shares

August 2nd, 2022 - Ryan Allway

Toronto, Ontario–(Newsfile Corp. – August 2, 2022) – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and naturally-derived approved drugs, is pleased to announce that it has raised $650,000 through the sale of debenture […]

Irwin Naturals Emergence Making Immediate Impact in New England

July 28th, 2022 - Ryan Allway

Company’s national rollup accelerating with acquisition of New Hampshire ketamine clinic LOS ANGELES, July 28, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) completed the acquisition of the assets of New England Ketamine, which is located in Salem, New Hampshire and serves clients in six different states in the […]

Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine

July 27th, 2022 - Ryan Allway

Silo shows reversal of allodynia and hyperalgesia using its selected formulation and partnered, patented delivery system ENGLEWOOD CLIFFS, N.J, July 27, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announced that its topically administered Ketamine reached a positive end point in an animal study. Silo’s formulation reduced mechanical allodynia and hyperalgesia […]

Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs

July 19th, 2022 - Ryan Allway

Company aims to increase health equity by developing more accessible treatment modalities better suited for existing healthcare infrastructure   DENVER, July 19, 2022 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, announced […]

Doseology Expands into US Retail Market

July 14th, 2022 - Ryan Allway

  VERNON, BC, July 14, 2022 /CNW/ – Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU7) (“Doseology” or the “Company”), a life sciences company focused on mental health and wellness, is excited to announce it has signed a Sales Management Agreement with Alternative Sales Management to act as the Company’s national sales manager for its expansion into the United […]

FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent On Novel Formulations of Palmitoylethanolamide, Presents Preclinical Toxicology Results at an International Symposium

July 13th, 2022 - Ryan Allway

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“ FSD Pharma ” or the “ Company ”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that is wholly owned subsidiary, Lucid Psycheceuticals Inc. (“ Lucid ”), filed a provisional patent application on novel formulations of palmitoylethanolamide (PEA). The new patent application […]

Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And Research Centre

July 13th, 2022 - Ryan Allway

  Partnership a unique opportunity to showcase Canada as a clinical and cultivation mecca   July 13, 2022 VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company cultivating and synthesizing high quality psychedelics and natural functional and psilocybin mushroom strains for transformational human experiences, […]

Nirvana Life Sciences Inc. Announces License for a Delivery System for Psychedelic APIs

July 6th, 2022 - Ryan Allway

VANCOUVER, BC, July 6, 2022 /CNW/ – Nirvana Life Sciences Inc. (Nirvana or the “Company”) (CSE: NIRV), a western Canadian based life sciences company aimed at developing psychedelic therapeutic medicines, including non-addictive chronic pain and relapse preventing products is pleased to announce it has acquired an exclusive license for the psychedelics sector for a novel delivery system for […]

BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies

July 6th, 2022 - Ryan Allway

VANCOUVER, British Columbia, July 06, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that a joint application to the Mitacs Accelerate program, in collaboration with Dr. Argel Aguilar-Valles at Carleton […]

Awakn Life Sciences Receives UK State Funding to Identify Optimal Pathway to Market in UK & US for Its Lead Clinical Development Program – Ketamine-Assisted Therapy for Alcohol Use Disorder

July 5th, 2022 - Ryan Allway

Awakn Provides Business Update on Progressing its Lead Program from Phase II b to Phase III Toronto, Ontario–(Newsfile Corp. – July 5, 2022) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954), a revenue-generating biotechnology company researching, developing and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), […]

Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder

June 27th, 2022 - Ryan Allway

— Marks the first novel psilocybin analog to enter clinical development — — Patient recruitment to commence immediately — — Pharmacokinetic and safety data readout expected in Q4 2022 —     TORONTO, June 27, 2022–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that it […]

PharmAla Biotech Registers Trademark for MDMA

June 24th, 2022 - Ryan Allway

The Company’s clinical-grade GMP MDMA product is now known as “Laneo”   VANCOUVER, June 24, 2022 (Canada Newswire) – PharmAla Biotech (CSE:MDMA) has registered a trademark for its clinical-grade MDMA product, which shall be marketed as Laneo MDMA. PharmAla is currently the only publicly-traded company to have developed a full manufacturing value chain for MDMA. […]

Nirvana Life Sciences announces filing of Patent for novel isolation of 4-PO-Psilocin Prodrug Compound

June 23rd, 2022 - Ryan Allway

VANCOUVER, BC, June 23, 2022 /CNW/ – Nirvana Life Sciences Inc. (Nirvana or the “Company”) (CSE: NIRV) a western Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products is pleased to report that it has filed a provisional patent application for a novel process for the isolation of a psychedelic 4-PO-Psilocin […]

Tryp Therapeutics Appoints New Chief Operating Officer

June 23rd, 2022 - Ryan Allway

Sid Taubenfeld with Extensive Experience in the Financial Markets and as a Biotech Executive Joins Tryp as Company Prepares to Expand Patient Access to Psilocybin-Based Treatments San Diego, California — (June 23, 2022) – Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases […]

Irwin Naturals Continues To Expand Clinic Footprint

June 21st, 2022 - Ryan Allway

LOS ANGELES, June 21, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) will add to its rapidly growing chain of psychedelic mental health centers, announcing today that it has signed a definitive agreement to acquire two clinics in Georgia.   Irwin has entered into a binding agreement to […]

Optimi Health Requests Approval To Manufacture MDMA, Other Synthetic Psychedelics

June 20th, 2022 - Ryan Allway

Company to maximize world-class EU-GMP operations, potentially opening future revenue- generating opportunities  June 20, 2022 VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”) or the (“Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, has submitted a request with Health Canada for an amendment […]

Lobe Sciences Announces Roadmap for Remainder of 2022 and Early 2023

June 14th, 2022 - Ryan Allway

Vancouver, British Columbia–(Newsfile Corp. – June 14, 2022) – Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBED) (“Lobe” or the “Company”), a Canadian Biopharmaceutical Company committed to discovering and developing psychedelic inspired medicines for the improvement of neurologic, brain and mental health disorders is reporting its roadmap for the remainder of 2022 and into 2023.   Philip Young […]

Silo Wellness Requests Oregon Property Owner Expressions of Interest for Collaborating on Psilocybin Licensing; Other Corporate Updates

June 14th, 2022 - Ryan Allway

Toronto, Ontario–(Newsfile Corp. – June 14, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or the “Company“), a leading global psychedelics company, announces a request for expressions of interests from Oregon property owners who may be considering participation in the regulatory regime under Oregon Ballot Measure 109. “With Silo Wellness […]

Lobe Sciences Ltd Announces Change in Record Date of Share Consolidation

June 9th, 2022 - Ryan Allway

Vancouver, British Columbia–(Newsfile Corp. – June 9, 2022) – Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (“Lobe” or the “Company”) announces that further to the Company’s June 6, 2022, news release, the record date for the six for one consolidation has been adjusted to June 10, 2022.   The Canadian Securities Exchange has published a […]

Silo Wellness Issues Shareholder Letter and Announces New Chief Executive Officer

June 9th, 2022 - Ryan Allway

Toronto, Ontario–(Newsfile Corp. – June 9, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or the “Company“), a leading global psychedelics company, announced today that Silo Wellness founder and chairman of the board of directors Mike Arnold is assuming the role of the Company’s interim chief executive officer to continue […]

TRYP Therapeutics Announces results of First Patient Dosed in its Phase II Clinical Trial for the Treatment of Binge Eating Disorder

June 9th, 2022 - Ryan Allway

  Initial data readout supports the potential effectiveness of psilocybin and psilocybin-related compounds for the treatment of Binge Eating Disorder San Diego, California — (June 9, 2022) – Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the […]

Nirvana Life Sciences Announces Positive Results for Addiction Relapse Prevention from Their Latest Pre-Clinical Psychedelic Drug Study

June 2nd, 2022 - Ryan Allway

Psilocybin reduced reinstatement of Heroin seeking behavior when administered immediately after a memory retrieval task in rats.   VANCOUVER, BC, June 2, 2022 /CNW/ – Nirvana Life Sciences Inc. (Nirvana or the “Company”) (CSE: NIRV),  a Canadian based life sciences company focused on developing novel therapeutic products derived from psychedelics to produce non-addictive solutions for opioid addiction […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading